N'-beta-L-Rhamnopyranosylindirubin

ID: ALA498148

Chembl Id: CHEMBL498148

PubChem CID: 135857533

Max Phase: Preclinical

Molecular Formula: C22H20N2O6

Molecular Weight: 408.41

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1O[C@H](N2C(=O)/C(=C3\Nc4ccccc4C3=O)c3ccccc32)[C@H](O)[C@H](O)[C@H]1O

Standard InChI:  InChI=1S/C22H20N2O6/c1-10-17(25)19(27)20(28)22(30-10)24-14-9-5-3-7-12(14)15(21(24)29)16-18(26)11-6-2-4-8-13(11)23-16/h2-10,17,19-20,22-23,25,27-28H,1H3/b16-15-/t10-,17-,19+,20+,22-/m0/s1

Standard InChI Key:  AVXRSJWDLOZVBS-ZUYNXGORSA-N

Alternative Forms

  1. Parent:

    ALA498148

    ---

Associated Targets(Human)

5637 (630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A-427 (643 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-MEL19 (54 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-MEL-103 (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 408.41Molecular Weight (Monoisotopic): 408.1321AlogP: 0.88#Rotatable Bonds: 1
Polar Surface Area: 119.33Molecular Species: NEUTRALHBA: 7HBD: 4
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 11.12CX Basic pKa: CX LogP: 0.93CX LogD: 0.93
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.52Np Likeness Score: 0.95

References

1. Libnow S, Methling K, Hein M, Michalik D, Harms M, Wende K, Flemming A, Köckerling M, Reinke H, Bednarski PJ, Lalk M, Langer P..  (2008)  Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines.,  16  (10): [PMID:18434163] [10.1016/j.bmc.2008.04.003]
2. Wang H, Wang Z, Wei C, Wang J, Xu Y, Bai G, Yao Q, Zhang L, Chen Y..  (2021)  Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.,  223  [PMID:34161865] [10.1016/j.ejmech.2021.113652]

Source